UCB Launches Legion Of Suits To Protect Epilepsy Drug IP

Law360, New York (July 11, 2013, 4:00 PM EDT) -- German pharmaceuticals giant UCB Pharma GmbH hit more than a dozen generic-drug manufacturers with suits in Delaware federal court Wednesday, accusing Sandoz Inc., Amneal Pharmaceuticals LLC, Apotex Corp. and others of infringing one of its patents by seeking approval for generic forms of UCB's epilepsy drug Vimpat.

The separate, virtually identical suits that UCB filed against 15 generic-drug companies, which also included Watson Laboratories Inc. and Hetero USA Inc., say the manufacturers infringed the patented formula for the anti-seizure medication by filing abbreviated new drug applications...
To view the full article, register now.